蛋白酪氨酸激酶

CAS号：859853-30-8

品名：(3R,4R)-4-氨基-1-[[4-[(3-甲氧基苯基)氨基]吡咯并[2,1-f][1,2,4]三嗪-5-基]甲基]哌啶-3-醇(3R,4R)-4-amino-1-[[4-(3-methoxyanilino)pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol

中文别名：(3R,4R)-4-氨基-1-[[4-[(3-甲氧基苯基)氨基]吡咯并[2,1-f][1,2,4]噻嗪-5-基]甲基]哌啶-3-醇;

英文别名：(3R,4R)-4-amino-1-({4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl}methyl)piperidin-3-ol;QCR-141;UNII-VKU5X213Q7;

分子式：C19H24N6O2

分子量：368.433

精确质量：368.196

Psa：100.94

密度：1.41

蛋白酪氨酸激酶

CAS号：859853-30-8

品名：(3R,4R)-4-氨基-1-[[4-[(3-甲氧基苯基)氨基]吡咯并[2,1-f][1,2,4]三嗪-5-基]甲基]哌啶-3-醇(3R,4R)-4-amino-1-[[4-(3-methoxyanilino)pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol

中文别名：(3R,4R)-4-氨基-1-[[4-[(3-甲氧基苯基)氨基]吡咯并[2,1-f][1,2,4]噻嗪-5-基]甲基]哌啶-3-醇;

英文别名：(3R,4R)-4-amino-1-({4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl}methyl)piperidin-3-ol;QCR-141;UNII-VKU5X213Q7;

分子式：C19H24N6O2

分子量：368.433

精确质量：368.196

Psa：100.94

密度：1.41

蛋白酪氨酸激酶

CAS号：1097917-15-1

品名：ASP3026;N2-[2-甲氧基-4-[4-(4-甲基-1-哌嗪基)-1-哌啶基]苯基]-N4-[2-[(1-甲基乙基)磺酰基]苯基]-1,3,5-三嗪-2,4-二胺2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-4-N-(2-propan-2-ylsulfonylphenyl)-1,3,5-triazine-2,4-diamine

中文别名：ASP3026;N2-[2-甲氧基-4-[4-(4-甲基-1-哌嗪基)-1-哌啶基]苯基]-N4-[2-[(1-甲基乙基)磺酰基]苯基]-1,3,5-三嗪-2,4-二胺

英文别名：CS-0787;QCR-144;N-[2-(isopropylsulfonyl)phenyl]-N'-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}-1,3,5-triazine-2,4-diamine;N-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}-N'-[2-(propane-2-sulfonyl)phenyl]-1,3,5-triazine-2,4-diamine;ASP3026;N2-[2-Methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-N4-[2-[(1-methylethyl)sulfonyl]phenyl]-1,3,5-triazine-2,4-diamine;UNII-HP4L6MXF10;

分子式：C29H40N8O3S

分子量：580.745

精确质量：580.294

Psa：127.43

MDL号：MFCD21609265

密度：1.3±0.1g/cm3

沸点：794.3±70.0°Cat760mmHg

闪点：434.2±35.7°C

折射率：1.620

储存条件：-20°C

蒸汽压：0.0±2.8mmHgat25°C

简介：ASP3026isanovelandselectiveanaplasticlymphomakinase(ALK)inhibitorthatshowspotentanti-tumoractivities.ASP3026alsoshowspotentialefficacyfornon-smallcelllungcancer(NSCLC)andisexpectedtoimprovethetherapeuticoutcomesofpatientswithcancerwithALKabnormality.